Cardiology

Shape Memory Medical Names Mary Dennehy as Vice President of Marketing

Friday, September 25, 2020 - 3:00pm

Shape Memory Medical Inc., developer of innovative therapies for cardiovascular and neurovascular markets, is pleased to announce and welcome Mary Dennehy as Vice President of Marketing.

Key Points: 
  • Shape Memory Medical Inc., developer of innovative therapies for cardiovascular and neurovascular markets, is pleased to announce and welcome Mary Dennehy as Vice President of Marketing.
  • Mary will be responsible for driving the development and implementation of global marketing strategies and initiatives that support commercialization of its Shape Memory Polymer embolization products and therapies.
  • I am very excited to join the Shape Memory Medical team and to be a part of an organization with such an innovative and unique portfolio, said Mary of her new position.
  • Shape Memory Medical Inc., based in Santa Clara, California, is dedicated to developing innovative therapeutic solutions with its proprietary Shape Memory Polymers.

Verve Therapeutics to Present at the Jefferies Virtual Gene Therapy/Editing Summit

Friday, September 25, 2020 - 1:00pm

Verve Therapeutics , a next-generation cardiovascular company, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Jefferies Virtual Gene Therapy/Editing Summit being held October 1-2, 2020.

Key Points: 
  • Verve Therapeutics , a next-generation cardiovascular company, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Jefferies Virtual Gene Therapy/Editing Summit being held October 1-2, 2020.
  • Dr. Kathiresan will present a corporate overview on Thursday, October 1, 2020, at 10:30 a.m.
  • In addition, Dr. Kathiresan will participate in a cardiovascular panel discussion on gene therapy on Thursday, October 1, 2020, at 2:00 p.m.
  • Verve Therapeutics is a biotechnology company created with a singular focus: to protect the world from heart disease.

Global Transcutaneous Oximetry Systems Market (2020 to 2025) - Growth, Trends, and Forecast - ResearchAndMarkets.com

Friday, September 25, 2020 - 10:12am

With transcutaneous monitoring, a sensor is gently applied to the body and continuously measures blood gases diffusing through the skin.

Key Points: 
  • With transcutaneous monitoring, a sensor is gently applied to the body and continuously measures blood gases diffusing through the skin.
  • Transcutaneous monitoring in neonates provides a real-time overview of the patient's often fluctuating oxygenation (tcpO2) and ventilation (tcpCO2) status.
  • These benefits have resulted in increase in demand for transcutaneous oximetry systems.
  • Hence, the market for transcutaneous oximetry systems is expected to grow.

Analysis of COVID-19 on Preclinical Animal Behavior Market | Market to See High Growth Due to the Increasing Prevalence of Chronic Conditions | Technavio

Thursday, September 24, 2020 - 2:30pm
Key Points: 
  • https://www.technavio.com/report/preclinical-animal-behavior-market-indu...
    The preclinical animal behavior market is driven by the increasing prevalence of various chronic diseases.
  • In addition, the increase in digitization and automation in healthcare is anticipated to boost the growth of the preclinical animal behavior market.
  • Therefore, the rising prevalence of chronic diseases is expected to drive the growth of the global preclinical animal behavior market during the forecast period.
  • Preclinical Animal Behavior Market End-user Outlook (Revenue, USD Million, 2020-2024)
    Preclinical Animal Behavior Market Geography Outlook (Revenue, USD Million, 2020-2024)

While 53% of US Physicians, 56% in the UK are Confident in Prescribing an Approved COVID-19 Vaccine, 42% in US Report their Patients are Vaccine Hesitant, According to Data from SurveyHealthcareGlobus

Thursday, September 24, 2020 - 1:30pm

These physicians estimate that 42% of US patients are vaccine hesitant, the highest level in the survey.

Key Points: 
  • These physicians estimate that 42% of US patients are vaccine hesitant, the highest level in the survey.
  • Findings were sourced by SurveyHealthcareGlobus (SHG), the global market leader of first-party healthcare data collection and custom survey solutions and part of the Apollo Intelligence, LLC family.
  • SHGs global COVID-19 vaccine hesitancy research found that on average physicians estimate 36% of their patients will be hesitant to receive a COVID-19 vaccine.
  • UK physicians report the lowest levels of hesitancy, at 27%, while German physicians estimate 41% of their patients will be hesitant, rivaling the US, at 42%.

Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

Thursday, September 24, 2020 - 12:00pm

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:

Key Points: 
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces participation at the following upcoming conferences:
    Gaurav Shah, M.D., President and CEO, is scheduled to participate in a fireside chat on Tuesday, October 6, 2020, at 2:30 p.m. Eastern Time.
  • A live audio webcast of the presentation will be available on the Investors section of the companys website, www.rocketpharma.com .
  • A replay of the presentation will be archived on the Rocket website following the conferences.
  • Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (Rocket) is advancing an integrated and sustainable pipeline of genetic therapies that correct the root cause of complex and rare childhood disorders.

Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting

Thursday, September 24, 2020 - 7:00am

In two presentations, Phase 3 results from the Imeglimin TIMES 2 and TIMES 3 (Trials of IMeglimin for Efficacy and Safety) trials were presented.

Key Points: 
  • In two presentations, Phase 3 results from the Imeglimin TIMES 2 and TIMES 3 (Trials of IMeglimin for Efficacy and Safety) trials were presented.
  • In the TIMES 2 trial, we observed clinically meaningful HbA1c reductions when Imeglimin was added to other oral approaches.
  • In the TIMES 3 trial, Imeglimin also demonstrated meaningful efficacy as an add-on to insulin in patients who were not well controlled.
  • Based on these results, we believe that Imeglimin has the potential to treat type 2 diabetes at multiple disease stages.

Vifor Pharma announces outcome of AFFIRM-AHF topline data

Thursday, September 24, 2020 - 6:00am

Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject (intravenous ferric carboxymaltose) on heart failure hospitalizations and cardiovascular mortality in iron-deficient patients hospitalized for acute heart failure (AHF), compared to placebo.

Key Points: 
  • Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject (intravenous ferric carboxymaltose) on heart failure hospitalizations and cardiovascular mortality in iron-deficient patients hospitalized for acute heart failure (AHF), compared to placebo.
  • Vifor Pharma Group strives to help patients around the world with severe and chronic diseases lead better, healthier lives.
  • Vifor Pharma Group holds a leading position in all its core business activities and consists of the following companies: Vifor Pharma; Vifor Fresenius Medical Care Renal Pharma (a joint company with Fresenius Medical Care); and OM Pharma.
  • Vifor Pharma Group is headquartered in Switzerland, and listed on the Swiss Stock Exchange (SIX Swiss Exchange, VIFN, ISIN: CH0364749348).

Outlook on the Global Peripheral Vascular Disease Market to 2024 - Developing and Potentially Disruptive Technologies

Wednesday, September 23, 2020 - 8:30pm

DUBLIN, Sept. 23, 2020 /PRNewswire/ -- The "Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 23, 2020 /PRNewswire/ -- The "Interventional Cardiology: Peripheral Vascular Disease Therapeutic Devices" report has been added to ResearchAndMarkets.com's offering.
  • In 2019, global sales of transdermal patch products targeting the conditions covered by this analysis totaled nearly $4.9bn, and is expected to increase at a CAGR of 2.4% over the forecast period, reaching $5.5bn in 2024.
  • Limiters include declines in mature market segments, and strong competition from oral pharmaceuticals and generic equivalents.
  • The report provides the following useful information:
    Medical device product portfolio overviews, by manufacturer
    In-depth market and competitive analysis.

Join the Heart Failure Society of America for the First Virtual Annual Scientific Meeting

Wednesday, September 23, 2020 - 6:32pm

The Heart Failure Society of America Virtual Annual Scientific Meeting 2020, taking place September 30 October 6, will feature more than 50 live, interactive scientific sessions, more than 400 abstracts, two Late Breaking Clinical Trials sessions, unique opportunities to connect with colleagues and much more.

Key Points: 
  • The Heart Failure Society of America Virtual Annual Scientific Meeting 2020, taking place September 30 October 6, will feature more than 50 live, interactive scientific sessions, more than 400 abstracts, two Late Breaking Clinical Trials sessions, unique opportunities to connect with colleagues and much more.
  • A virtual meeting uniquely provides greater flexibility and accessibility for attendees.
  • Find more information on HFSA Virtual ASM 2020 at https://hfsa.org/annualscientificmeeting or follow the meeting on social media using #HFSA2020.
  • The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy.